🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very proud of Justin Sharim MD for our new book on learning cardiac CT link.springer.com/book/10.1007/9…

#Inflammation plays a substantial role in the formation & progression of atherosclerotic plaque leading to #heartdisease. The EKSTROM trial data shows low-dose colchicine could significantly reduce total plaque volume after 1 year: radcliffecardiology.com/video-index/ac…

These are certainly interesting and important data. We look forward to studying further the unique risk profile of Lean Mass Hyper-Responders. They have a lot to teach us.

Completed another prospective serial CCTA trial, this one with Repatha from the great Cedars Sinai team under Dan Berman MD- authors.elsevier.com/a/1kso%7E,i2Xs…

a nice short paper on when is too young for a CAC scan? academic.oup.com/ehjcimaging/ad…

There has been a tremendous amount of interest in our new paper: jacc.org/doi/10.1016/j.… 1/5) While we appreciate the interest, there have been some comments that are unbecoming of fellow clinicians and academics. Let me clarify key points in this thread 🧵👇 **

These lean, metabolically healthy individuals on a #ketodiet exhibited less coronary plaque and lower rates of plaque progression than I would have expected, with the majority exhibiting minimal progression and several exhibiting regression. This is interesting.

However, this does not mean that this population is immune to atherosclerosis — obviously. Like any population, the KETO-CTA participants exhibited a heterogeneous risk profile, and a minority exhibited more rapid progression, as expected.

Importantly —in the population at large (including those with and without CAC at baseline), neither LDL nor ApoB predicted plaque progression, whereas baseline plaque predicted plaque progression. This is novel, a contribution to the literature, and warrants further investigation

This is the first of a set of papers, with more published data coming soon. I would ask fellow professionals to keep social media dialogue civil and especially that those parties without experience conducting research keep their juvenile attacks to themselves.

Finally, these patients were on no other treatments, anti-hypertensives, statins, or other therapies to slow plaque, so a true natural history study, different from many other drug therapy studies. Adrian Soto-Mota Nick Norwitz @bschermd@realDaveFeldman Khurram Nasir JACC Journals

Dr Alo, as you have published ZERO papers in your lifetime, and have no credibility in the field, calling my work dishonest is not acceptable. The change in NCPV was less than the change in PAV%, as shown in figure 1 in the paper, so if anything we put our worst foot forward.

This is the first of a set of papers, with more published data coming soon. I would ask fellow professionals to keep social media dialogue civil and suggest especially that those parties without experience conducting research keep their juvenile attacks to themselves.

This Position Statement from Principle Investigator Matthew Budoff MD ended up as dispersed tweets. I've compiled them for clarity 👇 There has been a tremendous amount of interest in our new paper: jacc.org/doi/10.1016/j.… While we appreciate the interest, there have been some

An excellent paper from my fellow Angelo De La Rosa who published great work on predicting CHF with CAC scans from MESA - authors.elsevier.com/c/1kxH36tu1iFD… continuing work we have been doing for > 20 years.

An excellent expert consensus document on statins in geriatrics. Also advocates for CAC scanning to help decision making (IIa recommendation). i am a strong advocate of treating older active adults with statins agsjournals.onlinelibrary.wiley.com/doi/full/10.11…

An important paper related to our work measuring liver fat on calcium scans showing semaglutide lowers liver fat in our prospective randomized trial - "STOP Trial" sciencedirect.com/science/articl… Novo Nordisk BDI